Oncternal Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $801 | $569 | $297 |
Gross Profit | -5,100 | -5,490 | -6,373 | |
EBITDA | -8,681 | -8,863 | -8,779 | -9,193 |
EBIT | -17,726 | -17,558 | -18,829 | |
Net Income | -8,464 | -8,559 | -8,388 | -9,164 |
Net Change In Cash | 0 | 801 | 569 | 297 |
Free Cash Flow | -6,953 | -5,822 | -7,438 | -6,419 |
Cash | 13,079 | 6,382 | 6,396 | 6,697 |
Basic Shares | 2,960 | 2,960 | 2,959 | 2,948 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $785 | $1,490 | $4,315 | $3,375 |
Gross Profit | -28,968 | 1,490 | 4,315 | 3,375 |
EBITDA | 2,235 | -44,245 | -31,333 | -17,542 |
EBIT | -39,479 | -44,947 | -31,366 | -17,542 |
Net Income | -39,479 | -43,393 | -31,300 | -17,209 |
Net Change In Cash | 785 | 1,490 | 4,315 | 3,375 |
Cost of Revenue | -53,623 | 96,686 | ||
Free Cash Flow | -32,164 | -36,704 | -26,589 | -17,495 |
Cash | 6,697 | 37,142 | 90,765 | 116,737 |
Basic Shares | 2,940 | 2,629 | 2,466 | 1,015 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$2.86 |
2024-06-30 | -$2.89 |
2024-03-31 | -$2.83 |
2023-12-31 | -$3.11 |
